226 related articles for article (PubMed ID: 25999349)
1. Endoplasmic reticulum targeting in Ewing's sarcoma by the alkylphospholipid analog edelfosine.
Bonilla X; Dakir el-H; Mollinedo F; Gajate C
Oncotarget; 2015 Jun; 6(16):14596-613. PubMed ID: 25999349
[TBL] [Abstract][Full Text] [Related]
2. Antitumor alkyl-lysophospholipid analog edelfosine induces apoptosis in pancreatic cancer by targeting endoplasmic reticulum.
Gajate C; Matos-da-Silva M; Dakir el-H; Fonteriz RI; Alvarez J; Mollinedo F
Oncogene; 2012 May; 31(21):2627-39. PubMed ID: 22056873
[TBL] [Abstract][Full Text] [Related]
3. Lipid rafts, endoplasmic reticulum and mitochondria in the antitumor action of the alkylphospholipid analog edelfosine.
Gajate C; Mollinedo F
Anticancer Agents Med Chem; 2014 May; 14(4):509-27. PubMed ID: 24628241
[TBL] [Abstract][Full Text] [Related]
4. In vitro and In vivo selective antitumor activity of Edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts.
Mollinedo F; de la Iglesia-Vicente J; Gajate C; Estella-Hermoso de Mendoza A; Villa-Pulgarin JA; de Frias M; Roué G; Gil J; Colomer D; Campanero MA; Blanco-Prieto MJ
Clin Cancer Res; 2010 Apr; 16(7):2046-54. PubMed ID: 20233887
[TBL] [Abstract][Full Text] [Related]
5. Endoplasmic reticulum stress in the proapoptotic action of edelfosine in solid tumor cells.
Nieto-Miguel T; Fonteriz RI; Vay L; Gajate C; López-Hernández S; Mollinedo F
Cancer Res; 2007 Nov; 67(21):10368-78. PubMed ID: 17974980
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo anti-schistosomal activity of the alkylphospholipid analog edelfosine.
Yepes E; Varela-M RE; López-Abán J; Dakir el H; Mollinedo F; Muro A
PLoS One; 2014; 9(10):e109431. PubMed ID: 25302497
[TBL] [Abstract][Full Text] [Related]
7. Suppression of metastatic organ colonization and antiangiogenic activity of the orally bioavailable lipid raft-targeted alkylphospholipid edelfosine.
Alonso-Pérez V; Hernández V; Calzado MA; Vicente-Blázquez A; Gajate C; Soler-Torronteras R; DeCicco-Skinner K; Sierra A; Mollinedo F
Biomed Pharmacother; 2024 Feb; 171():116149. PubMed ID: 38266621
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of alkylphospholipid edelfosine in prostate cancer models and endoplasmic reticulum targeting.
Dakir EH; Gajate C; Mollinedo F
Biomed Pharmacother; 2023 Nov; 167():115436. PubMed ID: 37683591
[TBL] [Abstract][Full Text] [Related]
9. Involvement of lipid rafts in the localization and dysfunction effect of the antitumor ether phospholipid edelfosine in mitochondria.
Mollinedo F; Fernández M; Hornillos V; Delgado J; Amat-Guerri F; Acuña AU; Nieto-Miguel T; Villa-Pulgarín JA; González-García C; Ceña V; Gajate C
Cell Death Dis; 2011 May; 2(5):e158. PubMed ID: 21593790
[TBL] [Abstract][Full Text] [Related]
10. Mitochondrial Targeting Involving Cholesterol-Rich Lipid Rafts in the Mechanism of Action of the Antitumor Ether Lipid and Alkylphospholipid Analog Edelfosine.
Mollinedo F; Gajate C
Pharmaceutics; 2021 May; 13(5):. PubMed ID: 34065546
[TBL] [Abstract][Full Text] [Related]
11. Mitochondria and lipid raft-located FOF1-ATP synthase as major therapeutic targets in the antileishmanial and anticancer activities of ether lipid edelfosine.
Villa-Pulgarín JA; Gajate C; Botet J; Jimenez A; Justies N; Varela-M RE; Cuesta-Marbán Á; Müller I; Modolell M; Revuelta JL; Mollinedo F
PLoS Negl Trop Dis; 2017 Aug; 11(8):e0005805. PubMed ID: 28829771
[TBL] [Abstract][Full Text] [Related]
12. Differential targets and subcellular localization of antitumor alkyl-lysophospholipid in leukemic versus solid tumor cells.
Nieto-Miguel T; Gajate C; Mollinedo F
J Biol Chem; 2006 May; 281(21):14833-40. PubMed ID: 16540473
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo efficacy of ether lipid edelfosine against Leishmania spp. and SbV-resistant parasites.
Varela-M RE; Villa-Pulgarin JA; Yepes E; Müller I; Modolell M; Muñoz DL; Robledo SM; Muskus CE; López-Abán J; Muro A; Vélez ID; Mollinedo F
PLoS Negl Trop Dis; 2012; 6(4):e1612. PubMed ID: 22506086
[TBL] [Abstract][Full Text] [Related]
14. Caenorhabditis elegans as a platform to study the mechanism of action of synthetic antitumor lipids.
Sánchez-Blanco A; Rodríguez-Matellán AG; Reis-Sobreiro M; Sáenz-Narciso B; Cabello J; Mohler WA; Mollinedo F
Cell Cycle; 2014; 13(21):3375-89. PubMed ID: 25485582
[TBL] [Abstract][Full Text] [Related]
15. The alkylphospholipid edelfosine shows activity against Strongyloides venezuelensis and induces apoptosis-like cell death.
Legarda-Ceballos AL; Rojas-Caraballo J; López-Abán J; Ruano AL; Yepes E; Gajate C; Mollinedo F; Muro A
Acta Trop; 2016 Oct; 162():180-187. PubMed ID: 27394030
[TBL] [Abstract][Full Text] [Related]
16. Potential use of imatinib in Ewing's Sarcoma: evidence for in vitro and in vivo activity.
Merchant MS; Woo CW; Mackall CL; Thiele CJ
J Natl Cancer Inst; 2002 Nov; 94(22):1673-9. PubMed ID: 12441322
[TBL] [Abstract][Full Text] [Related]
17. Mitochondrial-derived ROS in edelfosine-induced apoptosis in yeasts and tumor cells.
Zhang H; Gajate C; Yu LP; Fang YX; Mollinedo F
Acta Pharmacol Sin; 2007 Jun; 28(6):888-94. PubMed ID: 17506948
[TBL] [Abstract][Full Text] [Related]
18. ERK1/2 acts as a switch between necrotic and apoptotic cell death in ether phospholipid edelfosine-treated glioblastoma cells.
Melo-Lima S; Lopes MC; Mollinedo F
Pharmacol Res; 2015; 95-96():2-11. PubMed ID: 25749008
[TBL] [Abstract][Full Text] [Related]
19. Induction of Apoptosis in Human Pancreatic Cancer Stem Cells by the Endoplasmic Reticulum-Targeted Alkylphospholipid Analog Edelfosine and Potentiation by Autophagy Inhibition.
Gajate C; Gayet O; Fraunhoffer NA; Iovanna J; Dusetti N; Mollinedo F
Cancers (Basel); 2021 Dec; 13(23):. PubMed ID: 34885233
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of SOX2 induces cell apoptosis and G1/S arrest in Ewing's sarcoma through the PI3K/Akt pathway.
Ren C; Ren T; Yang K; Wang S; Bao X; Zhang F; Guo W
J Exp Clin Cancer Res; 2016 Mar; 35():44. PubMed ID: 26969300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
